- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02211196
Evidence-Based Tobacco Cessation Strategies in Patients With Cancer
Implementing Evidence-Based Tobacco Cessation Strategies in Oncology Clinics
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
PRIMARY OBJECTIVES:
I. To assess oncology providers' self-reported need for training on evidence-based tobacco cessation strategies and assess their level of interest in future training on evidence-based tobacco cessation strategies.
II. To test the feasibility of the implementation of evidence-based tobacco cessation strategies in community oncology clinics.
III. To test the feasibility of surveying community oncology patients after a clinic visit to assess provider behavior regarding screening and brief intervention for tobacco use.
OUTLINE:
Patients complete a survey over approximately 10-15 minutes related to their provider's cessation advice and assistance with quitting.
After completion of study, patients are followed up at 1 month.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
North Carolina
-
Winston-Salem, North Carolina, États-Unis, 27157
- Comprehensive Cancer Center of Wake Forest University
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- All patients with cancer who saw a provider will be eligible
Exclusion Criteria:
- Having a nurse or lab visit only
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Recherche sur les services de santé
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Health Services Research (smoking cessation intervention)
Participants complete a survey over approximately 10-15 minutes related to their provider's cessation advice and assistance with quitting.
|
Etudes annexes
Etudes annexes
Receive evidence-based tobacco cessation strategies
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage of providers from the Piedmont Oncology Association (POA) reporting a need for training on evidence-based tobacco cessation strategies
Délai: Up to 1 month
|
Will be estimated and 95% confidence intervals (CI) constructed.
|
Up to 1 month
|
|
Percentage reporting feeling very confident in their ability to counsel smokers
Délai: Up to 1 month
|
Will be estimated and 95% CI constructed.
|
Up to 1 month
|
|
Percentage reporting they would be willing to participate in training on evidence-based tobacco cessation strategies
Délai: Up to 1 month
|
Will be estimated and 95% CI constructed.
|
Up to 1 month
|
|
Proportion of oncology patients willing to complete a survey in an oncology clinic
Délai: Up to 1 month
|
Will be estimated and 95% CI constructed.
|
Up to 1 month
|
|
Proportion of patients who report that their provider asked about tobacco use during their visit
Délai: Up to 1 month
|
These prevalences will be estimated at pre- and post-intervention, and 95% CIs calculated adjusting for the expected within-clinic correlation of patient outcomes.
These outcomes will be analyzed further using a subject-specific modeling approach to account for the correlation that occurs due to patients being clustered within clinics.
|
Up to 1 month
|
|
Proportion of current smokers who report that their provider advised them to quit during their visit and provided tobacco-cessation strategies
Délai: Up to 1 month
|
These prevalences will be estimated at pre- and post-intervention, and 95% CIs calculated adjusting for the expected within-clinic correlation of patient outcomes.
These outcomes will be analyzed further using a subject-specific modeling approach to account for the correlation that occurs due to patients being clustered within clinics.
|
Up to 1 month
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Erin Sutfin, Wake Forest University Health Sciences
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- IRB00021885
- P30CA012197 (Subvention/contrat des NIH des États-Unis)
- NCI-2014-01572 (Identificateur de registre: CTRP (Clinical Trial Reporting Program))
- CCCWFU #99413 (Autre identifiant: Comprehensive Cancer Center of Wake Forest University)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .